Transmyocardial laser therapy for severe refractory angina

Institute for Clinical Systems Improvement
Record ID 32003000570
English
Authors' objectives:

This review aims to assess the available evidence on the effectiveness of transmyocardial laser therapy for severe refractory angina.

Authors' recomendations: With regard to transmyocardial laser therapy for patients with severe angina not amenable to conventional therapy, the ICSI Technology Assessment Committee finds: The morbidity and mortality associated with transmyocardial laser therapy, while not insignificant, are similar to the morbidity and mortality associated with CABG and PTCA in a similar population of patients. In randomized, controlled trials, angina class is typically reduced and quality of life is typically improved following transmyocardial laser therapy. Despite a demonstrated clinical benefit, there is no demonstrated improvement in myocardial perfusion or left ventricular ejection fraction. (Conclusion Grade I based on Class A evidence). The efficacy of this therapy beyond one year is currently unknown. Patients should be encouraged to enroll in clinical trials (if available) that will compare transmyocardial laser therapy with less invasive, less risky procedures or that will evaluate the use of transmyocardial laser therapy in combination with other procedures. Cost benefit analyses are also needed.
Authors' methods: Review
Details
Project Status: Completed
Year Published: 2000
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Angina Pectoris
  • Lasers
Contact
Organisation Name: Institute for Clinical Systems Improvement
Contact Address: 8009 34th Avenue South, Suite 1200, Bloomington, MN, USA. Tel: +1 952 814 7060; Fax: +1 952 858 9675
Contact Name: icsi.info@icsi.org
Contact Email: icsi.info@icsi.org
Copyright: Institute for Clinical Systems Improvement (ICSI)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.